NCT00189774已完成2 期
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 7
研究概览
简要总结
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes mellitus under the treatment with pioglitazone
排除标准
- •Patients who cannot follow the diet therapy and/or exercise therapy
- •Type 1 diabetes mellitus
研究者
研究点 (7)
Loading locations...
相似试验
终止
4 期
Pioglitazone for the Treatment of Bipolar DepressionBipolar DisorderInsulin ResistanceNCT01717040University Hospitals Cleveland Medical Center37
已完成
3 期
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic PatientsDiabetesNCT00461617Kissei Pharmaceutical Co., Ltd.291
已完成
4 期
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or RosiglitazoneType 2 DiabetesNCT00402909Novartis Pharmaceuticals28
已完成
2 期
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)Non-alcoholic Fatty Liver DiseaseFatty Liver, NonalcoholicNAFLDNonalcoholic SteatohepatitisNonalcoholic Fatty Liver DiseaseNCT05877547Merck Sharp & Dohme LLC381
终止
4 期
Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II DiabetesType 2 Diabetes MellitusNCT01862263Novartis Pharmaceuticals191